Attention-Deficit/Hyperactivity Disorder (ADHD)
5
Pipeline Programs
4
Companies
6
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
3
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
GUANFACINE HYDROCHLORIDEApproved
guanfacine
Unknown Companyoral2023
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs1
atomoxetinePhase 43 trials
Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHDN/A
Active Trials
N
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
City TherapeuticsGuanfacine
Eli Lilly and Companyatomoxetine
Eli Lilly and Companyatomoxetine
NeurocentriaNRCT-101SR
Merck & Co.MK0249
Eli Lilly and Companyatomoxetine
Clinical Trials (6)
Total enrollment: 178 patients across 6 trials
Treating Young Children With Attention Deficit Hyperactivity Disorder
Start: Feb 2026Est. completion: Jul 2030
Phase 4Not Yet Recruiting
Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
Start: Nov 200536 patients
Phase 4Unknown
Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
Start: Feb 2004Est. completion: Mar 200840 patients
Phase 4Completed
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
Start: Jan 2024Est. completion: Nov 2025
Phase 2/3Terminated
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
Start: Jul 2007Est. completion: Apr 200872 patients
Phase 2Completed
Efficacy of Atomoxetine in the Neuropsychological Tests Among Children With ADHD
Start: Jul 2007Est. completion: Jun 200830 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space